Shay Shemesh insider trades
Open-market stock purchases and sales by Shay Shemesh, Chief Dev. & Ops. Officer at Nuvectis Pharma, Inc, from SEC Form 4 filings since Feb 4, 2022.
Track record: 56% of 18 scored buys are up 5% or more since purchase, averaging +16%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jan 6, 2026 | NVCT Nuvectis Pharma, Inc | Bought (not open market) | — |
Companies traded
- NVCT Nuvectis Pharma, Inc: 18 buys, last Jan 6, 2026